药物洗脱植入物治疗慢性鼻窦炎:循证综述与推荐
可吸收药物洗脱植入物获得A级证据,推荐在精心选择的患者中考虑使用;非可吸收植入物因临床疗效证据不足不推荐;抗生素及其他药物洗脱植入物证据不足。
要点
- 可吸收药物洗脱植入物证据等级A,推荐用于精心选择的CRS患者。
- 非可吸收药物洗脱植入物因疗效证据不足,不推荐使用。
- 抗生素及其他药物洗脱植入物缺乏足够证据,无法形成推荐。
核心结论
- 可吸收类固醇洗脱植入物推荐用于精心选择的慢性鼻窦炎患者。
- 非可吸收药物洗脱植入物因临床疗效证据极少而不推荐。
- 抗生素和其他药物洗脱植入物缺乏足够证据支持推荐。
研究设计与样本
- 系统综述检索PubMed、EMBASE、Cochrane Review及灰色文献数据库,时间范围为1990年1月至2019年2月。
- 通过获益-危害评估、价值判断和迭代过程形成推荐。
主要发现
- 可吸收药物洗脱植入物获得高综合证据等级(A级)。
- 非可吸收药物洗脱植入物支持临床疗效的证据极少。
- 抗生素和替代药物洗脱植入物缺乏足够证据。
关键数值与推荐
- 可吸收药物洗脱植入物:证据等级A,推荐在精心选择的患者中考虑使用。
- 非可吸收药物洗脱植入物:不推荐使用。
- 抗生素和替代药物洗脱植入物:证据不足,无法推荐。
临床怎么用
- 临床可考虑在精心选择的CRS患者中使用可吸收类固醇洗脱植入物。
- 避免使用非可吸收药物洗脱植入物,因其临床疗效证据不足。
- 抗生素和其他药物洗脱植入物需等待更多证据后再评估使用。
局限性
- 需要进一步研究以明确合适的患者选择标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Drug-eluting implants are becoming increasingly popular in the treatment of chronic rhinosinusitis (CRS). A previous attempt to make an evidence-based recommendation was hindered by limited evidence and experience with these implants. Since that time, the body of literature discussing drug-eluting implants has grown rapidly. The objective of this study was to review drug-eluting implants designed for use in the sinonasal cavity through an evidence-based review with recommendations. METHODS: A systematic review of the literature was performed using PubMed, EMBASE, Cochrane Review, and gray literature databases from January 1990 through February 2019 to examine drug-eluting implants used in CRS. Benefit-harm assessments, value judgments, and recommendations were made based on the available evidence. Study exclusion criteria included studies unavailable in English and non-endoscopic sinus surgeries. All authors agreed on recommendations through an iterative process. RESULTS: Thirty-one studies were included in the final analysis. Absorbable drug-eluting implants achieved a high aggregate grade of evidence (A), with a recommendation for their use to be considered in carefully selected patients. Nonabsorbable drug-eluting implants were recommended against due to minimal evidence supporting clinical efficacy. Antibiotic and alternative drug-eluting implants lack sufficient evidence for recommendations. CONCLUSION: Absorbable steroid-eluting implants are recommended for carefully selected patients with CRS. Additional research to define appropriate patient selection is needed.
引用
- Smith KA, Kingdom TT, Gray ST, et al. Drug-eluting implants in chronic rhinosinusitis: an evidence-based review with recommendations. Int Forum Allergy Rhinol. 2020. PMID: 32479698. doi:10.1002/alr.22565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。